🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Catherine Wood’s XBI Holdings & Trades

First Buy
Q2 2026
Duration Held
1 Quarters
Largest Add
Q2 2026
+94 Shares
Current Position
94 Shares
$14,822 Value

Catherine Wood's XBI Position Overview

Catherine Wood (via Ark Investment Management LLC) currently holds 94 shares of State Street SPDR S&P Biotech ETF (XBI) worth $14,822, representing 0.00% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Catherine Wood has initiated a new position in XBI, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Catherine Wood's State Street SPDR S&P Biotech ETF (XBI) Holding Value Over Time

Track share changes against reported price movement

Quarterly State Street SPDR S&P Biotech ETF (XBI) Trades by Catherine Wood

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2026 +94 New Buy 94 $157.68

Catherine Wood's State Street SPDR S&P Biotech ETF Investment FAQs

Catherine Wood first purchased State Street SPDR S&P Biotech ETF (XBI) in Q2 2026, acquiring 94 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Catherine Wood has held State Street SPDR S&P Biotech ETF (XBI) for 1 quarters since Q2 2026.

Catherine Wood's largest addition to State Street SPDR S&P Biotech ETF (XBI) was in Q2 2026, adding 94 shares worth $14,822.

According to the latest 13F filing for Q2 2026, Catherine Wood's firm, Ark Investment Management LLC, owns 94 shares of State Street SPDR S&P Biotech ETF (XBI), valued at approximately $14,822.

As of the Q2 2026 filing, State Street SPDR S&P Biotech ETF (XBI) represents approximately 0.00% of Catherine Wood's publicly disclosed stock portfolio, making it one of their key holdings.

Catherine Wood's peak holding in State Street SPDR S&P Biotech ETF (XBI) was 94 shares, as reported at the end of Q2 2026.